NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Arvinas, Inc. (ARVN) Stock Analysis

Arvinas, Inc. (ARVN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ARVN

$7.56

−$0.11 (−1.37%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARVN with… →

ARVN Key Statistics

As of Oct 21, 2026
Trading
Open
$7.62
Previous Close
$7.66
Day's Range
7.54–7.79
52-Week Range
6.74–14.51
Volume
653.39K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.81
Valuation
Market Cap
$487.46M
P/E Ratio
29.06
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.54
EPS (ttm)Profit attributable to each share over the last twelve months.
0.26
Financials (FY)
Revenue (FY)
$262.60M−0.30%
Net Income (FY)
−$80.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
2.94%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.52M
1-Year Return
−21.79%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
802.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ARVN closed at $7.56, −21.79% over 1 year.

Arvinas, Inc. (ARVN) has a market capitalization of $487.46M.

In fiscal 2025, ARVN reported revenue of $262.60M.

ARVN Stock Return by Calendar Year

Arvinas, Inc. (ARVN) return since Sep 2018: what $10,000 became

1 year
$10,000 $7,821
−21.79%
5 years
$10,000 $858
−91.42%
Since Sep 2018
$10,000 $4,707
−52.93%

If you had invested $10,000 in Arvinas, Inc. (ARVN) at the close on September 27, 2018, the earliest close on record here, it would have been worth $4,707 at the close on October 21, 2026: −52.93% in total, −8.92% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−36.30%
2025−38.13%
2024−53.43%
2023+20.32%
2022−58.35%
2021−3.29%
2020+106.69%
2019+219.77%
2018 (partial year)−19.94%

As of October 21, 2026.

ARVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$262.60M−$80.80M−30.8%
2024$263.40M−$198.90M−75.5%
2023$78.50M−$367.30M−467.9%
2022$131.40M−$282.50M−215.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$262.60M—−$118.50M−$80.80M−30.8%
2024$263.40M—−$250.20M−$198.90M−75.5%
2023$78.50M—−$401.50M−$367.30M−467.9%
2022$131.40M—−$263.20M−$282.50M−215.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARVN Valuation vs Biotechnology Median

Median of 608 stocks
MetricARVNBiotechnology medianvs median
P/E29.0616.6075% above
P/S ratio1.5413.300.1x the median
Profit margin2.94%−38.31%41.2 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Arvinas, Inc. (ARVN) at $487.46M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 246.

ARVN last closed at $7.56 on October 21, 2026. That is −$0.11 (−1.37%) against the previous close. The 52-week range on file runs from $6.74 to $14.51. The latest close sits 12.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $262.60M. That is −0.30% against the prior fiscal year, when revenue was $263.40M. The same year closed with a net loss of $80.80M. The reported profit margin is 2.94%. That is 41.2 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 0.26.

Across the 4 fiscal years on file, revenue moves from $131.40M in 2022 to $262.60M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 29.06. That is 75.06% above the Biotechnology median of 16.6. The price-to-sales ratio is 1.54. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −21.79%. Measured over 5 years, that is −38.81% a year compounded. The reported beta is 1.81. Daily returns over the trailing 8 years annualize to a volatility of 76.71%.

Growth & Income

The record shows no dividend for ARVN.

2026 is still running; the total return is −36.30% year to date. The strongest complete calendar year on file is 2019 at +219.77%; the weakest is 2022 at −58.35%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Arvinas, Inc. (ARVN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arvinas, Inc. ARVN $487.46M 29.1
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Arvinas, Inc. trades at a P/E of 29.1.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Arvinas, Inc.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Visit website →